Full Text
PT26 Cost-Effectiveness Analysis of Sunvozertinib as a Second-line Treatment for Advanced Non-Small Cell Lung Cancer with EGFR exon20ins Mutation: An Economic Evaluation Based on MAIC

Abstract

Authors

Xiaoyan Guan Xiaoning He

Back to Volume 28, Supplemental Issue 6S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×